Table 2:
Sociodemographic, clinical and virologic characteristics of study participants with chronic HBV by FLD status
| 1: No FLD | 2: Steatosis | 3: Steatohepatitis | Overall | Pairwise P-valuesb | |||
|---|---|---|---|---|---|---|---|
| n=289a | N=77a | n=55a | P-value b | 1 vs 2 | 1 vs 3 | 2 vs 3 | |
| Age, years, | <0.001 | 0.047 | <0.001 | 0.047 | |||
| Median (25th:75th) | 40 (32: 51) | 43 (35: 53) | 47 (42: 56) | ||||
| Female, n (%) | 117 (40.5%) | 24 (31.2%) | 17 (30.9%) | 0.18 | |||
| Race, n (%) | n=287 | 0.57 | |||||
| White | 27 (9.4%) | 10 (13.0%) | 6 (10.9%) | ||||
| Black | 26 (9.1%) | 4 (5.2%) | 3 (5.5%) | ||||
| Asian | 226 (78.7%) | 63 (81.8%) | 44 (80.0%) | ||||
| Other | 8 (2.8%) | 0 (0.0%) | 2 (3.6%) | ||||
| Past year alcohol use, n (%) | n=235 | n=68 | n=48 | 0.29c | |||
| None/minimal | 169 (71.9%) | 42 (61.8%) | 34 (70.8%) | ||||
| Low-risk | 48 (20.4%) | 21 (30.9%) | 8 (16.7%) | ||||
| At-risk | 18 (7.7%) | 5 (7.4%) | 6 (12.5%) | ||||
| BMI category (race-specific), n (%) | n=250 | n=67 | n=51 | <0.001 c | <0.001 | <0.001 | 0.02 |
| Underweight/Normal | 121 (48.4%) | 13 (19.4%) | 4 (7.8%) | ||||
| Overweight | 95 (38.0%) | 33 (49.3%) | 22 (43.1%) | ||||
| Obese | 34 (13.6%) | 21 (31.3%) | 25 (49.0%) | ||||
| Hyperlipidemia, n (%) | n=235 | n=67 | n=48 | 0.16 | |||
| Yes | 37 (15.7%) | 11 (16.4%) | 13 (27.1%) | ||||
| Hypertension, n (%) | n=236 | n=67 | n=48 | <0.001 | 0.003 | <0.001 | 0.03 |
| Yes | 42 (17.8%) | 24 (35.8%) | 27 (56.3%) | ||||
| Diabetes, n (%) | n=236 | n=67 | n=48 | <0.001 | 0.22 | <0.001 | 0.01 |
| Yes | 11 (4.7%) | 6 (9.0%) | 14 (29.2%) | ||||
| Chronic HBV phenotype, n (%) | n=239 | n=66 | n=50 | 0.08 | |||
| Immune tolerant | 0 (0.0%) | 1 (1.5%) | 0 (0.0%) | ||||
| HBeAg-positive | 90 (37.7%) | 25 (37.9%) | 11 (22.0%) | ||||
| HBeAg-negative | 83 (34.7%) | 22 (33.3%) | 25 (50.0%) | ||||
| Inactive carrier | 14 (5.9%) | 2 (3.0%) | 0 (0.0%) | ||||
| Indeterminant | 52 (21.8%) | 16 (24.2%) | 14 (28.0%) | ||||
| HBV Genotype, n (%) | n=260 | n=71 | n=50 | 0.76 | |||
| A | 39 (15.0%) | 9 (12.7%) | 8 (16.0%) | ||||
| B | 97 (37.3%) | 30 (42.3%) | 24 (48.0%) | ||||
| C | 96 (36.9%) | 28 (39.4%) | 15 (30.0%) | ||||
| D | 18 (6.9%) | 2 (2.8%) | 1 (2.0%) | ||||
| Other/multiple | 10 (3.8%) | 2 (2.8%) | 2 (4.0%) | ||||
| ALT (U/L) | n=252 | n=69 | n=52 | 0.53 | |||
| Median (25th:75th) | 60.5 (36: 98.5) | 58 (43: 86) | 67 (46: 93) | ||||
| ALT X ULN, n (%) | n=252 | n=69 | n=52 | 0.02 c | 0.45 | 0.058 | 0.45 |
| 0 to 1 | 29 (11.5%) | 3 (4.3%) | 1 (1.9%) | ||||
| >1 to 2 | 83 (32.9%) | 24 (34.8%) | 14 (26.9%) | ||||
| >2 | 140 (55.6%) | 42 (60.9%) | 37 (71.2%) | ||||
| AST (U/L) | n=230 | n=67 | n=48 | 0.29 | |||
| Median (25th:75th) | 40 (29: 65) | 41 (30: 55) | 51.5 (33: 63) | ||||
| AST X ULN, n (%) | n=230 | n=67 | n=48 | 0.27 c | |||
| 0 to 1 | 118 (51.3%) | 30 (44.8%) | 17 (35.4%) | ||||
| >1 to 2 | 72 (31.3%) | 32 (47.8%) | 24 (50.0%) | ||||
| >2 | 40 (17.4%) | 5 (7.5%) | 7 (14.6%) | ||||
| HBV DNA (log10 IU/mL) | n=253 | n=70 | n=52 | 0.16 | |||
| Median (25th:75th) | 5.7 (4.2: 7.7) | 6.0 (4.0: 8.1) | 5.3 (3.3: 6.7) | ||||
| HBeAg status, n (%) | n=246 | n=70 | n=51 | 0.049 | 0.79 | 0.057 | 0.057 |
| Positive | 101 (41.1%) | 30 (42.9%) | 12 (23.5%) | ||||
| Quantitative HBsAg (log10 IU/mL) | n=158 | n=50 | n=36 | 0.02 | 0.78 | 0.01 | 0.07 |
| Median (25th:75th) | 3.6 (3.0: 4.2) | 3.7 (2.8: 4.5) | 3.1 (2.8: 3.4) | ||||
Abbreviations: ALT, Alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DNA, deoxyribonucleic acid; FLD, fatty liver disease; HBV, Hepatitis B virus; HBeAg, quantitative hepatitis B e-antigen; HBsAg, quantitative hepatitis B surface antigen; ULD, upper limit of normal.
a
Unless otherwise noted within the table.
b
Comparing all three groups. When p<0.05 pairwise comparisons were performed, with Holm’s adjustment for 3 comparisons.
c
From the Jonckheere Trend Test.